Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1997651 citationsJournal Article

Authors

Sandra M. Swain · Breast Center

Fredrick S. Whaley · Breast Center

Mirjam C. Gerber · Breast Center

Stuart P. Weisberg · Breast Center

Michael York · Breast Center

Darcy Spicer · Breast Center

Sarah E. Jones · Breast Center

Abstract

DZR had a significant cardioprotective effect as measured by noninvasive testing and clinical CHF. One of the two studies (088001) showed a lower response rate with DZR, but time to progression and survival were not significantly different. DZR is the first agent shown to reduce cardiotoxicity from doxorubicin.

Topics & Keywords

Chemotherapy-induced cardiotoxicity and mitigation Cancer Treatment and Pharmacology Chemotherapy-related skin toxicity

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 15, Issue 4, pp. 1318-1332

DOI: 10.1200/jco.1997.15.4.1318

Field-Weighted Citation Impact: 12.13